Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
Resistance to EGFR Tyrosine Kinase Inhibitor Therapy in Non-Small-Cell Lung Cancer via Newly Acquired Targetable Oncogenic Driver Alterations With an Emphasis on BRAF: Case Series and Literature Review of Treatment. JCO precision oncology Giustini, N. P., Patel, S. P., Myall, N. J., Fernando do Prado Moura, J., Kulkarni, A., Chao, R. C., Wakelee, H., Bazhenova, L. 2022; 6: e2100551
View details for DOI 10.1200/PO.21.00551
View details for PubMedID 35952324